News

Cerillo® Announces Partnership with Opentrons to Deliver Automated Microbiome Research Solutions

Cerillo®, a technology company developing advanced research platforms for microbiome studies, today announced a partnership with Opentrons Labworks, Inc., a leading force in lab automation. The collaboration not only grants researchers access to entry-level lab automation but also extends the reach of Cerillo’s comprehensive suite of microbiome research tools, fostering standardization and efficiency in laboratory processes .

Cerillo and Opentrons are automating microbiome research and the discovery of microbiome therapeutics by seamlessly integrating Cerillo’s miniaturized Alto™ and Stratus® microplate readers onto the OT-2 and Flex for deck ELISA and cell growth analysis. This integration enables easy setup of experiments, including bacterial co­culture studies with Cerillo’s Co-culture platform.

According to Eric Mayton, CEO of Cerillo, “The integration of Cerillo’s products with Opentrons’ platforms aligns with our mission to provide accessible, cost effective, user-friendly laboratory tools that efficiently standardize global microbiome research at the bench. Our alignment with Opentrons’ open-source robotics platform sets new standards for industry efficiency.”

Cerillo’s Microbiome Discovery Platform

The Cerillo Microbiome Discovery Platform offers a comprehensive suite of tools to tackle the challenges of microbiome research head-on. This interconnected platform introduces unprecedented efficiencies, elevating data standardization, reproducibility, and analysis of research findings. Cerillo’s innovative platform includes:

Co-Culture Duet System®: Cerillo’s off-the-shelf microbial interaction platform features duets with porous barriers, allowing researchers to physically isolate populations while maintaining fluidic contact. This enables the observation, study, and growth measurement of individual microbial populations alongside others.

Miniaturized Microplate Readers: Cerillo’s compact microplate readers, like the next-generation Alto™, are ten times smaller than standard ones, perfect for monitoring measurements in tight spaces and anaerobic chambers. Alto is also Ideal for ELISA and high-throughput microbial growth curve applications.

Canopy Wireless Accessory Package: Cerillo’s revolutionary SaaS package offers wireless capabilities and robust software analytics so that researchers can experience real-time data visualization, monitoring, and wireless control of their microplate readers and scale their experiments by connecting multiple readers simultaneously.

 

Learn more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation